title: Preventive effects of Juzen-taiho-to on N-methyl-N-nitrosourea and estradiol-17beta-induced endometrial carcinogenesis in mice.
abstract: Two experiments were conducted to determine effects of Juzen-taiho-to on endometrial carcinogenesis in mice. In the first experiment, Juzen-taiho-to treatment (2 weeks) decreased the levels of estradiol-17beta (E(2))-stimulated expression of c-fos/jun mRNA and their oncoproteins, determined by reverse transcription-polymerase chain reaction and Southern blot analysis, and the immunohistochemical method, in the uteri of ovarectomized mice. For the second experiment, 93 female ICR mice were given N-methyl-N-nitrosourea (MNU) solution (1 mg/100 g body weight) and normal saline (as controls) into their left and right uterine corpora, respectively, and were divided into four groups. Group 1 was given a diet containing 0.2% Juzen-taiho-to and 5 p.p.m. E(2). Group 2 was given a diet containing 5 p.p.m. E(2) alone. Group 3 was given a diet containing 0.2% Juzen-taiho-to alone. Group 4 was kept on the basal diet alone and treated as a control. Juzen-taiho-to treatment significantly decreased incidences of the uterine endometrial atypical (P<0.01), complex (P<0.05) and simple hyperplasias (P<0.01), under estrogenic stimulation. It is suggested that Juzen-taiho-to has an inhibitory effect on E2-related endometrial carcinogenesis in mice, relevantly through suppression of estrogen-induced c-fos/jun-expression.
authors: Department of Obstetrics and Gynecology and Department of Pathology, Gifu University School of Medicine, 40 Tsukasa-machi, Gifu-city 500-8705, Japan. kniwa@cc.gifu-u.ac.jp
authors: K
authors: K
authors: Niwa
authors: M
authors: M
authors: Hashimoto
authors: S
authors: S
authors: Morishita
authors: Z
authors: Z
authors: Lian
authors: K
authors: K
authors: Tagami
authors: H
authors: H
authors: Mori
authors: T
authors: T
authors: Tamaya
mesh_terms: D000818:Animals; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D015139:Blotting, Southern; D001835:Body Weight / Q000187:drug effects; D002273:Carcinogens; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D016889:Endometrial Neoplasms / Q000139:chemically induced* / Q000517:prevention & control*; D004958:Estradiol / Q000378:metabolism*; D005260:Female; D007150:Immunohistochemistry; D008770:Methylnitrosourea; D051379:Mice; D008813:Mice, Inbred ICR; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D016755:Proto-Oncogene Proteins c-jun / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors; D014599:Uterus / Q000378:metabolism
chemical_list: D016588:Anticarcinogenic Agents; D002273:Carcinogens; D004365:Drugs, Chinese Herbal; D016760:Proto-Oncogene Proteins c-fos; D016755:Proto-Oncogene Proteins c-jun; D012333:RNA, Messenger; C063587:juzentaihoto; D004958:Estradiol; D008770:Methylnitrosourea